Who to call at BioCryst Pharmaceuticals, Inc., and when
Fundz watches for the moments BioCryst Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day BioCryst Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioCryst Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioCryst Pharmaceuticals, Inc.. With Fundz connected, it knows.
BioCryst Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
http://www.biocryst.com/AI Executive Summary
AI-powered analysis of 8-K filing content
BioCryst agreed to acquire Astria Therapeutics through a merger in which Astria stockholders would receive 0.59 BioCryst shares plus $8.55 in cash per share. BioCryst also added Astria's President and CEO, Jill C. Milne, Ph.D., to its board, a change that ties the leadership transition to the pending deal.
Key Takeaways
Astria stockholders would receive 0.59 shares of BioCryst common stock plus $8.55 in cash for each Astria common share, with cash in lieu of fractional shares and dissenting appraisal-rights holders e
Astria's Series X Convertible Preferred Stock would convert into the same Merger Consideration, based on the common shares each preferred share is convertible into.
3 more takeaways
Related Filings (14)
14 more filings from BioCryst Pharmaceuticals, Inc. in the last 90 days
Filing Overview
What This Means
BioCryst Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.